Trailing Twelve Months Revenue Growth: Alumis Pharma (ALMS)

Brandmark of Alumis Inc. (ALMS)

Alumis Inc. is pursuing premium pricing through innovative treatments for immune pathologies. The LTM sales growth YoY metric confirms this trajectory, with the current parameter standing at -67.50. The stability of biologic distribution is ensured by a precise cold chain, while post-IPO financial resilience allows the company to cover expenses for the final trial stages of oral inhibitors.

Alumis Inc. (ALMS): Revenue Growth YoY (Last 12 Months) from 11/23/2025 to 11/17/2026

Summary analytical data breakdowns for Alumis (ALMS)

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Fundamental company valuation:ALMS (Alumis Pharma)
Original product of alumis.com

This indicator measures the revenue growth rate over a rolling twelve-month period, neutralizing quarterly volatility to determine the actual trajectory of business development. For Alumis Inc., which develops targeted therapies for immune pathologies, the year-over-year revenue trend over the last 12 months serves as a marker for the commercialization of innovations, allowing investors to assess the market acceptance of drugs against the backdrop of the company's clinical successes.